Why Ultragenyx Pharmaceutical Inc.’s (RARE) Stock Is Up 5.03%
As of Wednesday, November 18, Ultragenyx Pharmaceutical Inc.’s RARE share price has surged by 5.03%, which has investors questioning if this is right time to sell.Michael Rose
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Michael Rose
Tudor Pop
Rosalio Madrigal
Cynthia McLaughlin
Jenna Brashear
| Share Statistics | RARE | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,696.1 | $208.2 | 53% |
|
| Shares Out (Mil) | 102.1 | 55.4 | 62% |
|
| Institutional Ownership | 96.6% | 92.9% | 70% |
|
| Float (Mil) | 77.4 | 40.7 | 55% |
|
| Beta | 0.36 | 1.00 | 19% |
|
| Avg Daily Volume (000s) | 4,390 | 570 | 90% |
|
| Price Change (52-week) |
(49.6%) | 40.7% | 21% |
|
| Growth | RARE | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 20.0% | 13.2% | 81% |
|
| Net Income (5yr) | (25.2%) | (10.3%) | 17% |
|
| EPS (5yr) | (13.7%) | 15.5% | 19 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (11.7%) | (15.7%) | 57% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 6 | 6 | 6 | |
| Current EPS | $0.655 | ($3.049) | $1.433 | |
| Month Ago EPS | ($0.662) | ($4.078) | $0.226 | |
| # Rev Up | 0 | 0 | 1 | |
| # Rev Down | 1 | 1 | 0 | |
| Three Months Ago EPS | ($0.074) | ($2.564) | $2.634 | |
| Year/Year Chg | (156.7%) | (47.7%) | (121.4%) | |
| Financials | RARE | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $730 | $39 | 45% |
|
| Net Income (TTM) (Mil) | ($524) | ($44) | 2% |
|
| EPS (TTM) | ($5.180) | ($1.400) | 7% |
|
| Operating Cash Flow (TTM) (Mil) | ($437) | ($34) | 2% |
|
| Net Cash Flow (TTM) (Mil) | na | $-0 | na |
|
| Long-Term Debt (Q1) (Mil) | $1,106 | $4 | 67% |
|
| Enterprise Value (Q1) (Mil) | $2,374 | $138 | 52% |
|
| Valuation | RARE | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 1.96 | na |
|
| P/E | na | 17.7 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.8 | na |
|
| Ratios | RARE | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (10.7%) | 67.9% | 3% |
|
| Net Margin | (71.8%) | (50.8%) | 9% |
|
| ROA | (44.1%) | (47.4%) | 12% |
|
| ROE | 285.7% | (51.6%) | 99% |
|
| Liabilities to Assets | 131.1% | 29.7% | 98% |
|
| F-Score | 3 | 3 | 18% |
|
Ultragenyx Pharmaceutical Inc. did not pass any screens on 11/17/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors